MS Speaks

Biogen Idec – Currently Recruiting Prospective Study Participants:



Study Summary – ALLOW Study

Biogen Idec is currently recruiting for its Phase IIIb ALLOW Study. The ALLOW Study is looking at an investigational medication for patients with relapsing multiple sclerosis (MS) that requires fewer injections than current interferon medications. The study will involve around 200 adults in the United States with this condition and will last for just over 1 year.

The investigational medication is currently being reviewed by the US Food and Drug Administration (FDA) as a potentially new treatment for relapsing multiple sclerosis (MS).

Participation

You may be able to take part in this study if you:

~are 18–65 years of age (inclusive)

~have been diagnosed with a relapsing form of MS
are currently taking an interferon beta medication (e.g. AVONEX® [interferon beta-1a], BETASERON® [interferon beta-1b], REBIF® [interferon beta-1a]) and have not changed your dose for at least 4 months

If you are able to take part, you will be treated, supported, and monitored carefully by a team of experienced medical staff. There will be no charge to you for the study medications, health checks, and medical care related to the study.

If Interested in Additional Study Information

Interested individuals may receive additional study information including the location of study sites within the United States by clicking here. This online screening tool uses study eligibility criteria and contact information to refer the interested individual to a site in your area.

The U.S. National Institutes of Health website, http://www.ClinicalTrials.gov also has study information. This information can be quickly located by typing the trial's identifier NCT01939002 in the website's "search for studies" box.

Risks of Participation

As with any clinical research study that involves an investigational medication, there is a chance of side effects. A detailed list of known possible side effects of the study medication is noted in the Informed Consent document for this trial. The clinical research staff will continually monitor participant safety. However, it is also important for participants to alert research staff should they experience side effects, or if they feel unwell during the study.